Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ferrari, R.
Right arrow Articles by Ceconi, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ferrari, R.
Right arrow Articles by Ceconi, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Angiotensin II overproduction: enemy of the vessel wall

R. Ferraria,1, G. Guardigli1, G. Cicchitelli1, M. Valgimigli1, E. Merli1, O. Soukhomorskaia1 and C. Ceconi2

1 Chair of Cardiology, University of Ferrara, Ferrara, Italy
2 Cardiovascular Research Centre, Salvatore Maugeri Foundation, Gussago, Brescia, Italy

a Correspondence: Prof. Roberto Ferrari, Universita' di Ferrara, Arcispedale S. Anna, Corso Giovecca, 203, 44100 Ferrara, Italy.

Abstract

Unfortunately, the vessel wall has several enemies and, regrettably, overproduction of angiotensin II seems to be one of the most aggressive, often causing several principal diseases such as arteriosclerosis, hypertension, coronary artery disease and heart failure. Obviously, it is unrealistic to consider angiotensin II as the only player but, certainly, it is one of the most important, as the reduction of its overproduction by drugs such as ACE inhibitors or angiotensin II receptor blockers is able to counteract the above mentioned pathological conditions. This review mainly deals with the importance of overproduction of angiotensin II in causing endothelial dysfunction and the mechanisms which are involved, such as the activation of angiotensin I and II which have opposite effects. It is clear that a precise picture of the molecular changes induced by angiotensin II at tissue level cannot yet be described although progress is continuously made at the additive role of oxidative stress and activation of the nuclear factor {kappa}B is addressed. The mechanism of action of ACE inhibitors and the angiotensin II receptor blockers is also highlighted in the attitude which is considering the biological effect of these drugs and rather than their pharmacological effects.

Key Words: Angiotensin II • angiotensin-converting enzyme inhibitors

References

  1. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens VA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25–49[Abstract]
  2. Nash DT. Comparative properties of angiotensin-converting enzyme inhibitors: relations with inhibition of tissue angiotensinconverting enzyme and potential clinical implications. Am J Cardiol. 1992;69:26C–32C[CrossRef][Medline]
  3. Cushman DW, Cheung HS. Concentrations of angiotensinconverting enzyme in tissues of the rat. Biochem Biophys Acta. 1971;20:261–265
  4. Booz GW, Baker KM. Role of type 1 and 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension. 1996;28:635–640[Abstract/Free Full Text]
  5. Sadoshima J. Cytokine actions of angiotensin II. Circ Res. 2000;86:1187–1189[Free Full Text]
  6. Horiuchi M, Lehtonen JY, Daviet I. Signalling mechanism of the AT2 angiotensin II receptor: cross-talk between AT1 and AT2 receptors in cell growth. Trends Endocrinol Metab. 1999;10:391–396[CrossRef][Web of Science][Medline]
  7. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res. 1990;66:883–890[Abstract/Free Full Text]
  8. Shai SY, Fishel RS, Martin BM, Berk BC, Bernstein KE. Bovine angiotensin converting enzyme cDNA cloning and regulation. Increased expression during endothelial cell growth arrest. Circ Res. 1992;70:1274–1281[Abstract/Free Full Text]
  9. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999;31:51–60[CrossRef][Web of Science][Medline]
  10. Lindpaimner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin converting enzyme gene polymorphism and the risk of ischaemic heart disease. N Engl J Med. 1995;332:706–711[Abstract/Free Full Text]
  11. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94:2756–2767[Abstract/Free Full Text]
  12. Moroi M, Zhang L, Yasuda T, et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998;101:1225–1232[Web of Science][Medline]
  13. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-anginine. Nature. 1988;333:664–666[CrossRef][Medline]
  14. Ferrari R, Guardigli G, Cicchitelli G, Valgimigli M, Soukomovskaia O, Ceconi C. Cardioprotection with ACE inhibitors, non-angiotensin II-related mechanisms. Eur Heart J. 2000;2(suppl 1):122–128
  15. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002–2012[Free Full Text]
  16. Ferrara R, Ceconi C, Curello S, Pepi P, Fazzoletti A, Visioli O. Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Card Drugs Ther. 1996;10:623–629[CrossRef]
  17. Gaussin V, Schneider MD. Surviving infarction one gene at a time: decreased remodelling and mortality in engineered mice lacking the angiotensin II type IA receptor. Circulation. 1999;100:2043–2044[Free Full Text]
  18. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res. 1999;85:643–650[Abstract/Free Full Text]
  19. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25:155–161[Abstract/Free Full Text]
  20. Patterson C, Ruef J, Madamanchi NR, et al. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin: evidence that p47Phox may participate in forming this oxidase in vitro and in vivo. J Biol Chem. 1999;274:19814–19822[Abstract/Free Full Text]
  21. Lassègue B, Sorescu D, Szöcs K, et al. Novel gpglphox homologues in vascular smooth moscle cells: nox 1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res. 2001;88:888–894[Abstract/Free Full Text]
  22. Wang HD, Xu S, Johns DG, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001;88:947–953[Abstract/Free Full Text]
  23. Dzau VJ. The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr Opin Nephrol Hypertens. 1993;2:27–32[Medline]
  24. Barnes PJ, Darin M. Nuclear factor-{kappa}B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–1071[Free Full Text]
  25. Xie QW, Kashiwabara Y, Nathan C. Role of trascription factor NF-{kappa}B/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269:4705–4708[Abstract/Free Full Text]
  26. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element ‘decoy’ against nuclear factor-{kappa}B binding site prevents myocardial infarction. Nat Med. 1997;3:894–899[CrossRef][Web of Science][Medline]
  27. Muller DN, Dechend R, Mervaala EM, et al. NF-{kappa}B inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000;35:193–201[Abstract/Free Full Text]
  28. Erl W, Hansson GK, de Martin R, Draude G, Weber KS, Weber C. Nuclear factor-{kappa}B regulates induction of apoptosis protein-1 expression in vascular smooth muscle cells. Circ Res. 1999;64:668–677
  29. Dichtl W, Nilsson L, Goncalves I, et al. Very low-density lipoprotein activates nuclear factor-{kappa}B in endothelial cells. Circ Res. 1999;84:1085–1094[Abstract/Free Full Text]
  30. Selzman CH, Shames BD, Reznikov LL, et al. Liposomal delivery of purified inhibitory-{kappa}B{alpha} inhibits tumour necrosis factor-{alpha}-induced human vascular smooth muscle proliferation. Cir Res. 1999;84:867–875[Abstract/Free Full Text]
  31. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182–1191[Abstract/Free Full Text]
  32. Jacob HJ, Lindpaintner K, Lincoln SE. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell. 1991;67:213–224[CrossRef][Web of Science][Medline]
  33. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641–644[CrossRef][Medline]
  34. Cambien F, Costerousse O, Tiret L, et al. Plasma level and gene polymorphism of angiotensin converting enzyme in relation to myocardial infarction. Circulation. 1994;90:669–676[Abstract/Free Full Text]
  35. Schunkert H, Hense HW, Danser J, Muscholl M, Luchmer A, Riegger AJG. Association between circulating components of the renin angiotensin aldosterone system and left ventricular mass. Br Heart J. 1997;77:24–31[Abstract/Free Full Text]
  36. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin converting enzyme gene polymorphism and the risk of ischaemic heart disease. N Engl J Med. 1995;332:706–711
  37. Lindpaintner K, Lee M, Larson MG, et al. Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med. 1996;334:1023–1028[Abstract/Free Full Text]
  38. Montgomery HE, Clarkson P, Dollery CM, et al. Association of the angiotensin converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 1997;96:741–747[Abstract/Free Full Text]
  39. Pinto YM, van Gilst WH, Kingma JH, Schunkert H. The deletion-type allele of the angiotensin converting enzyme gene is associated with progressive ventricular dilatation after anterior myocardial infarction. J Am Coll Cardiol. 1995;25:1622–1626[Abstract]
  40. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–1346

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ferrari, R.
Right arrow Articles by Ceconi, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ferrari, R.
Right arrow Articles by Ceconi, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?